Ryan Deschner
Stock Analyst at Raymond James
(2.69)
# 1,813
Out of 4,818 analysts
9
Total ratings
55.56%
Success rate
19.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INZY Inozyme Pharma | Maintains: Outperform | $24 → $12 | $0.98 | +1,122.37% | 1 | Mar 12, 2025 | |
| TRVI Trevi Therapeutics | Upgrades: Strong Buy | $9 → $29 | $6.28 | +362.15% | 2 | Mar 10, 2025 | |
| ARDX Ardelyx | Reiterates: Strong Buy | $15 → $13 | $4.86 | +167.77% | 1 | Feb 21, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $14.40 | +94.51% | 3 | Jan 14, 2025 | |
| LQDA Liquidia | Upgrades: Strong Buy | $27 | $13.58 | +98.82% | 2 | Aug 19, 2024 |
Inozyme Pharma
Mar 12, 2025
Maintains: Outperform
Price Target: $24 → $12
Current: $0.98
Upside: +1,122.37%
Trevi Therapeutics
Mar 10, 2025
Upgrades: Strong Buy
Price Target: $9 → $29
Current: $6.28
Upside: +362.15%
Ardelyx
Feb 21, 2025
Reiterates: Strong Buy
Price Target: $15 → $13
Current: $4.86
Upside: +167.77%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $14.40
Upside: +94.51%
Liquidia
Aug 19, 2024
Upgrades: Strong Buy
Price Target: $27
Current: $13.58
Upside: +98.82%